Artelo Partners with AI Leader to Uncover Dose-Responsive Biomarkers for ART26.12
Artelo Biosciences has entered a strategic collaboration with AI firm ScienceMachine to leverage its proprietary platform for analysis of internal FABP5 datasets, accelerating identification of mechanisms and biomarkers for ART26.12 based on Phase 1 single ascending dose trial data. Preliminary AI-driven analyses have uncovered novel protein and lipid signatures correlated with ART26.12’s dose-responsive analgesic effect in healthy volunteers, informing follow-on compound prioritization and future biomarker strategies.
1. Strategic Collaboration with ScienceMachine
Artelo Biosciences and ScienceMachine launched a partnership in 2025 to apply cutting-edge AI agent technology to Artelo’s large FABP5 datasets, aiming to shorten R&D timelines and reduce costs in the development of FABP5 inhibitors.
2. AI-Driven Data Analysis Platform
ScienceMachine’s platform automates interrogation of multi-omic and Phase 1 single ascending dose (ART26.12-100) data, extracting latent biological networks and potential mechanisms of action in a fraction of the time required by traditional methods.
3. Early Biomarker and Mechanistic Insights
Initial analyses have identified novel protein indicators of FABP5 target engagement and lipid signatures linked to ART26.12’s dose-responsive analgesic effect in healthy volunteers, offering testable hypotheses for clinical biomarker strategies.
4. Pipeline Expansion and Next Steps
These insights enable Artelo to prioritize follow-on compounds from its FABP5 inhibitor library with greater confidence, guide design of future clinical studies, and plan publication of psoriasis model results later this year.